DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing ...

It has had strong momentum since November, but there is still plenty of upside left.

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Dexcom achieved FY25 revenues of around $4.66bn, corresponding to a 16% uplift over FY24.

Researchers who use Fitabase to capture data from Fitbit and Garmin devices will soon be able to capture a new kind of data: continuous glucose monitoring data from Dexcom products. The ability to ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

In a surprising turn of events, shares of Dexcom Inc. (NASDAQ:DXCM) took a nosedive in pre-market trading following the company’s decision to lower its full-year sales forecast for glucose monitoring ...